Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SHK.0b013e31822f8336 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prophylaxis by a reversible cholinesterase inhibitor and the treatment NMDA receptor antagonists as combinatorial countermeasure against nerve agent poisoning in mice model.
Chem Biol Interact
January 2025
Department of Toxicology and Military Pharmacy, Military Faculty of Medicine, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic; Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, Hradec Kralove, Czech Republic. Electronic address:
The current pharmacological pretreatment and medical treatment of nerve agent poisoning is an insufficiently addressed medical task. The prophylactic efficacy of a novel compound acting dually as an acetylcholinesterase inhibitor and NMDA receptor antagonist (K1959) and the therapeutic efficacy of a novel NMDA receptor antagonist (K2060) were evaluated in the NMRI mice model of nerve agent poisoning by tabun, soman and sarin. Their added value to the standard antidotal treatment (a combination of oxime reactivator and atropine) was also analyzed.
View Article and Find Full Text PDFCoronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy.
JACC CardioOncol
December 2024
The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Background: Premenopausal risk-reducing salpingo-oophorectomy (RRSO) in women at high familial risk of ovarian cancer leads to immediate menopause. Although early natural menopause is associated with increased cardiovascular disease risk, evidence on long-term cardiovascular disease risk after early surgical menopause is scarce.
Objectives: We sought to determine the long-term influence of the timing of RRSO on the development of coronary artery calcium (CAC), an established marker for cardiovascular disease risk.
Home Visit Survey on Outpatient Antibiotic Use: Assessing Leftover Medications and Factors Influencing Appropriate Use by Community Pharmacists.
J Infect Chemother
January 2025
Kyoto Pharmaceutical Association, 563 Bairincho, Higashiyama-ku, Kyoto, 605-0863, Japan. Electronic address:
This cross-sectional study investigated the prevalence and factors associated with leftover antibiotics in Japanese households through pharmacist home visits. The research, conducted in collaboration with pharmaceutical associations in Kyoto and Hirakata, included 37 cases analyzed from October 2023 to March 2024. Participants had a median age of 81 years and received a median of two antibiotic prescriptions in the past year.
View Article and Find Full Text PDFRoutine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
Vaccine
January 2025
Jenner Institute, Old Road Campus Research Building, University of Oxford, Oxford OX3 7DQ, UK.
Background: Pre-exposure prophylactic rabies vaccination (PrEP) is advised for travellers to countries with high rabies incidence, but rarely available for local residents. Some studies suggest poor cost-effectiveness of PrEP in such settings, but have generally focused upon post-exposure prophylaxis (PEP) cost savings as the main benefit of PrEP, without considering lives saved by PrEP efficacy.
Methods: We compared incremental cost-effectiveness ratios (ICERs) of use of rabies PrEP, against an alternative of using only PEP, by adapting a decision-tree model previously used to inform Gavi's investment in rabies PEP.
Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study.
Gynecol Oncol
January 2025
Department of Pathology of UFCSPA and Department of Pathology of Irmandade de Santa Casa de Misericórdia de Porto Alegre (ISCMPA), Brazil.
Objective: To evaluate the efficacy of actinomycin D (ActD) as prophylactic chemotherapy (P-chem) in patients with high-risk complete hydatidiform mole (Hr-CHM) on progression to gestational trophoblastic neoplasia (GTN).
Methods: From 1996 to 2023, 426 Hr-CHMs were selected in a cohort of 1623 patients with gestational trophoblastic disease (GTD). From 1996 to 2023, 290 patients with Hr-CHMs received a single bolus dose of Act-D at the time of uterine evacuation (Hr-CHM P-chem group); 136 with the same risk factors did not receive P-chem (Hr-CHM control group).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!